Using blood tests to detect and monitor colorectal cancer
Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer
This study is testing if a blood test can help find and track colorectal cancer in patients who are about to have a colonoscopy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Helse Nord-Trøndelag HF Academic / other |
| Locations | 1 site (Levanger) |
| Trial ID | NCT06307938 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of circulating tumor DNA (ctDNA) as a liquid biopsy for diagnosing and monitoring colorectal cancer. It aims to determine if ctDNA markers can identify colorectal cancer patients among those scheduled for colonoscopy and how these markers correlate with cancer subtype and progression. Participants will provide blood samples and complete a questionnaire to aid in the analysis. The study focuses on the clinical utility of ctDNA in improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are scheduled for a colonoscopy.
Not a fit: Patients under 18 years old or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection and more personalized treatment for colorectal cancer patients.
How similar studies have performed: Other studies have shown promise in using ctDNA for cancer detection, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥ 18 years old summoned for colonoscopy * Patient able to understand and sign written informed consent Exclusion Criteria: * Patient \< 18 years old * Patient unable to understand or give written informed consent * Patient unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator as unlikely to complete the study
Where this trial is running
Levanger
- Nord-Trøndelag Hospital Trust — Levanger, Norway (Recruiting)
Study contacts
- Study coordinator: Eivor A Laugsand, MD, PhD
- Email: eivor.a.laugsand@ntnu.no
- Phone: +47 74075180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.